Resources
9 Results (showing 1 - 9)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/28/2024 (updated 4/4/2024)
This presentation suggested RCORP grantees and the behavioral health system in general should scale up parenting classes provided to clients across the continuum.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Independence Ballroom on Wednesday, March 4, 2020, at 2:45 PM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Monument Room on Wednesday, March 4, 2020, at 2:45 PM
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.
RSV 2023 Session: Quick Response Teams: Preventing Deaths While Sharing the Hope of Recovery (Day 1)
Posted 7/26/2023 (updated 3/28/2024)
The presentation discussed the development and changes in the utilization of a Quick Response Team in an Ohio rural community.
Posted 7/26/2023 (updated 3/28/2024)
Effective prevention includes Design, Development, and Delivery. This session addressed the critical need to follow the science, what the science is, and how the Randolph County Caring Community (RCCC) has Designed, Developed, and Delivered an evidence-based prevention system in their area. Participants learned how the PROSPER (PROmoting School-community-university Partnerships to Enhance Resilience) model has brought additional partners to its consortium, leading to the use of tested and effective prevention programs.
Posted 6/7/2022 (updated 3/27/2024)
This workshop examined the behavioral health trends of children, youth, and young adults in rural communities and best practices to increase behavioral health treatment outcomes.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.